Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo Activity

  • J Med Chem. 2021 Nov 25;64(22):16598-16608. doi: 10.1021/acs.jmedchem.1c01174.
Declan M Gorman  1 ,  Xaria X Li  1 ,  John D Lee  1 ,  Jenny N Fung  1 ,  Cedric S Cui  1 ,  Han Siean Lee  1 ,  Barbara E Rolfe  2 ,  Trent M Woodruff  1  3 ,  Richard J Clark  1
Affiliations
  • 1. School of Biomedical Sciences, The University of Queensland, Brisbane, Queensland 4072, Australia.
  • 2. Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland 4072, Australia.
  • 3. Queensland Brain Institute, The University of Queensland, Brisbane, Queensland 4072, Australia.
PMID: 34762432 DOI: 10.1021/acs.jmedchem.1c01174
Abstract

The anaphylatoxin C5a is a complement peptide associated with immune-related disorders. C5a binds with equal potency to two GPCRs, C5aR1 and C5aR2. Multiple C5a peptide agonists have been developed to interrogate the C5a receptor function but none show selectivity for C5aR1. To address these limitations, we developed potent and stable peptide C5aR1 agonists that display no C5aR2 activity and over 1000-fold selectivity for C5aR1 over C3aR. This includes BM213, which induces C5aR1-mediated calcium mobilization and pERK1/2 signaling but not β-arrestin recruitment, and BM221, which exhibits no signaling bias. Both ligands are functionally similar to C5a in human macrophage cytokine release assays and in a murine in vivo neutrophil mobilization assay. BM213 showed antitumor activity in a mouse model of mammary carcinoma. We anticipate that these C5aR1-selective agonists will be useful research tools to investigate C5aR1 function.

Products